<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053872</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269521</org_study_id>
    <secondary_id>SIOP-PNET-4</secondary_id>
    <secondary_id>EU-20244</secondary_id>
    <secondary_id>UKCCSG-CNS-2003-05</secondary_id>
    <nct_id>NCT00053872</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma</brief_title>
  <official_title>A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Giving radiation therapy in different ways with combination chemotherapy may kill any&#xD;
      remaining tumor cells following surgery. It is not yet known which radiation therapy regimen&#xD;
      combined with combination chemotherapy is more effective in treating medulloblastoma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare different radiation therapy regimens plus&#xD;
      combination chemotherapy in treating children who have undergone surgery for medulloblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the event-free survival rate in pediatric patients with standard-risk&#xD;
           medulloblastoma treated with conventional vs hyperfractionated radiotherapy and&#xD;
           vincristine followed by maintenance with cisplatin, lomustine, and vincristine.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the pattern of relapse, especially local relapse (tumor bed or posterior fossa&#xD;
           outside tumor bed), in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the toxicity of surgery and whether there are identifiable factors that&#xD;
           correlate with toxicity in these patients.&#xD;
&#xD;
        -  Determine the impact of any surgical complications on commencement of adjuvant therapy&#xD;
           and event-free survival of these patients.&#xD;
&#xD;
        -  Compare late sequelae, in terms of health status, endocrine deficiencies, and hearing&#xD;
           loss, in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      country. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Within 28-40 days after surgical resection, patients undergo conventional&#xD;
           fractionated radiotherapy once daily, 5 days a week, for 6-7 weeks. Patients also&#xD;
           receive vincristine IV once weekly for 8 weeks.&#xD;
&#xD;
        -  Arm II: Beginning as in arm I, patients undergo hyperfractionated radiotherapy twice&#xD;
           daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine as in arm I.&#xD;
&#xD;
        -  Maintenance chemotherapy:Six weeks after completion of radiotherapy, all patients&#xD;
           receive cisplatin IV over 6 hours and oral lomustine on day 1 and vincristine IV on days&#xD;
           1, 8, and 15. Treatment repeats every 6 weeks for 8 courses.&#xD;
&#xD;
      Patients are followed at least every 6 months for 3 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 316 patients (158 per treatment arm) will be accrued for this&#xD;
      study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of event-free survival at 3 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of neurosurgery</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed medulloblastoma, including the following variants:&#xD;
&#xD;
               -  Classic&#xD;
&#xD;
               -  Nodular/desmoplastic&#xD;
&#xD;
               -  Large cell&#xD;
&#xD;
               -  Melanotic&#xD;
&#xD;
               -  Medullomyoblastoma&#xD;
&#xD;
          -  Prior total or subtotal surgical removal of tumor within the past 28-40 days&#xD;
&#xD;
               -  No more than 1.5 cm^2 residual tumor by early postoperative MRI or CT scan&#xD;
&#xD;
          -  No brainstem or supratentorial primitive neuroectodermal tumor&#xD;
&#xD;
          -  No atypical teratoid rhabdoid tumor&#xD;
&#xD;
          -  No known predisposition to medulloblastoma (e.g., Gorlin's syndrome)&#xD;
&#xD;
          -  No CNS metastasis (supratentorial, arachnoid of the posterior fossa, or craniospinal&#xD;
             axis) by MRI&#xD;
&#xD;
          -  No clinical evidence of metastasis outside the CNS&#xD;
&#xD;
          -  No tumor cells in lumbar cerebrospinal fluid by cytospin&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hematological function less than CTC grade 2&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function less than CTC grade 2&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Renal function less than CTC grade 2&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to receive radiotherapy twice daily&#xD;
&#xD;
          -  Vital functions within age-appropriate normal range&#xD;
&#xD;
          -  Audiological function less than CTC grade 2&#xD;
&#xD;
          -  No medical contraindication to radiotherapy or chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent dexamethasone as an antiemetic allowed, provided all other therapies have&#xD;
             failed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent cobalt irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior treatment for brain tumor or any other malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitta Lannering, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ostra Sjukhuset</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Vizcaya</city>
        <zip>48</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostra Sjukhuset</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <keyword>untreated childhood medulloblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

